PRD Therapeutics, Inc.

We’re pleased to announce the close of a $8.75M (¥1.3B) Series A financing led by JAFCO. They are joined by new investors JIC Venture Growth Investments, Mizuho Capital and SMBC Venture Capital. We also thank existing investor, TAIHO INNOVATIONS, for their continued support in this round. PRD Therapeutics is developing PRD001, First-in-Class lipid metabolism regulator. We further accelerate the development of PRD001 to contribute to HoFH and NASH patients as soon as possible.